Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC
Sign Up to like & getrecommendations! Published in 2017 at "Cancer treatment and research"
DOI: 10.1016/j.ctarc.2017.02.005
Abstract: Erlotinib and gefitinib are first generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Afatinib is a second generation pan-Her EGFR TKI. All three TKIs have demonstrated superiority to chemotherapy in the first line… read more here.
Keywords: egfr mutation; egfr wild; type benefit; paradigm egfr ... See more keywords